Brooklyn FI LLC Acquires Shares of 594,919 SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)

Brooklyn FI LLC acquired a new position in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 594,919 shares of the company's stock, valued at approximately $677,000. Brooklyn FI LLC owned about 0.85% of SELLAS Life Sciences Group at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Anson Funds Management LP boosted its stake in SELLAS Life Sciences Group by 50.2% during the fourth quarter. Anson Funds Management LP now owns 1,192,266 shares of the company's stock worth $1,240,000 after acquiring an additional 398,431 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of SELLAS Life Sciences Group by 21.2% during the fourth quarter. Geode Capital Management LLC now owns 733,546 shares of the company's stock valued at $763,000 after purchasing an additional 128,355 shares during the period. Opus Capital Group LLC boosted its position in shares of SELLAS Life Sciences Group by 5.5% during the 4th quarter. Opus Capital Group LLC now owns 238,500 shares of the company's stock worth $248,000 after purchasing an additional 12,400 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of SELLAS Life Sciences Group by 33.6% during the 4th quarter. Northern Trust Corp now owns 134,721 shares of the company's stock worth $140,000 after purchasing an additional 33,878 shares in the last quarter. 17.38% of the stock is owned by institutional investors and hedge funds.

SELLAS Life Sciences Group Trading Down 1.2%

SELLAS Life Sciences Group stock traded down $0.02 during midday trading on Friday, reaching $1.69. The stock had a trading volume of 2,659,748 shares, compared to its average volume of 1,532,409. The company has a fifty day moving average price of $1.42 and a two-hundred day moving average price of $1.24. SELLAS Life Sciences Group, Inc. has a 12 month low of $0.77 and a 12 month high of $2.12. The company has a market capitalization of $168.62 million, a P/E ratio of -2.45 and a beta of 2.34.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04. On average, equities research analysts predict that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current fiscal year.

SELLAS Life Sciences Group Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.